Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €0.72 EUR
Change Today -0.026 / -3.47%
Volume 0.0
4UL On Other Exchanges
As of 10:03 AM 11/27/15 All times are local (Market data is delayed by at least 15 minutes).

unilife corp (4UL) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/27/15 - €4.21
52 Week Low
10/28/15 - €0.63
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for UNILIFE CORP (4UL)

Related News

No related news articles were found.

unilife corp (4UL) Related Businessweek News

View More BusinessWeek News

unilife corp (4UL) Details

Unilife Corporation designs, manufactures, and supplies injectable drug delivery systems in the United States and internationally. The company offers Unifill, a pre-filled syringe with integrated, automatic, and user-controlled retraction; Unifill Finesse, an integrated, automatic, and user-controlled retraction with standard plunger seal and plunger rod; Unifill Select, which allows an end-user to select and attach a needle at the time of injection; Unifill Nexus that is equipped with an integrated luer adapter to provide connectivity with needleless luer access devices; and Unifill Allure, that allows the end-user to select and attach a needle with a universal luer connection at the time of injection with automatic, user-controlled needle retraction. It also provides ReadyToGo, a portfolio of wearable injectors for pre-filled, disposable devices that can be worn by a patient over periods; Imperium platform, a prefilled, disposable, and multi-day wearable insulin pump; and LISA smart reusable and RITA disposable auto-injectors. In addition, the company offers drug reconstitution delivery systems, such as AutoMix Presto, an automatic reconstitution for single-step mixing and injection; EZMix Genesis, a ventless one-step reconstitution and automatic user-controlled retraction; EZMix Engage to attach and retract a needle; and EZMix Prodigy, a single-barrel reconstitution system with a pre-fillable syringe. Further, it provides ocular delivery systems comprising Ocu-ject for the delivery of microliter sized doses to the eye; Ocu-mix, a dual-chamber syringe platform to reconstitute or mix, and deliver various therapies into the eye with a single injection; and Depot-ject, which places a drug depot into the eye. Additionally, the company offers Micro-ject to optimize the delivery of therapies with microliter doses. It serves pharmaceutical and biotechnology companies. The company was founded in 2002 and is headquartered in York, Pennsylvania.

278 Employees
Last Reported Date: 09/14/15
Founded in 2002

unilife corp (4UL) Top Compensated Officers

Chairman of the Board, Chief Executive Office...
Total Annual Compensation: $840.0K
President and Chief Operating Officer
Total Annual Compensation: $742.8K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $124.2K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $489.0K
Chief Accounting Officer, Senior Vice Preside...
Total Annual Compensation: $367.8K
Compensation as of Fiscal Year 2015.

unilife corp (4UL) Key Developments

Unilife Corporation Approves Amendment of Article Fourth of Certificate of Incorporation

Unilife Corporation held its Annual Meeting of Stockholders on November 16, 2015. At the 2015 Annual Meeting, the stockholders approved an amendment of Article FOURTH of the company's Certificate of Incorporation to increase the number of authorized shares of common stock, par value $0.001 per share, from 250,000,000 to 350,000,000.

Unilife Corporation Reports Unaudited Consolidated Earnings Results for the First Quarter Ended September 30, 2015

Unilife Corporation reported unaudited consolidated earnings results for the first quarter ended September 30, 2015. For the quarter, revenue was $3,187,000 against $1,380,000 a year ago. Operating loss was $23,588,000 against $18,896,000 a year ago. Net loss was $25,864,000 or $0.21 per basic and diluted net loss share against $22,262,000 or $0.21 per basic and diluted net loss share a year ago. Adjusted net loss was $18,451,000 or $0.15 per basic and diluted net loss share against $15,935,000 or $0.15 per basic and diluted net loss share a year ago.

Unilife Corporation Signs Supply Agreement with MedImmune

Unilife Corporation announced the signing of the first supply agreement with MedImmune, the global biologics research and development arm of AstraZeneca. This supply agreement, executed on October 30, 2015, provides commercial terms for long-term supply of a customized device from Unilife's Precision-Therapy™ platform of wearable injectors for a monoclonal antibody in late-stage clinical studies in MedImmune's pipeline. The supply agreement follows the master terms defined in the MDSA for the customization and supply of Unilife's wearable injectors for use with MedImmune's drug candidates. The customization phase of the lead wearable injector program for Medimmune is now nearing completion and device production has begun at Unilife.  Additionally,Unilife is shipping wearable injectors to MedImmunethis quarter. In addition to development and material fees already paid by MedImmune, Unilife will begin generating revenue from the sale of these devices in the current quarter of this fiscal year. Unilife has now completed its device component design verification and successful independent human factors studies for this device, as well as the qualification of filling of this wearable injector drug container for future filling on high-speed biopharmaceutical filling lines. This new Supply Agreement provides minimum purchase commitments from MedImmune for the initial four years following the commercial launch of this biologic, and also has unit pricing for the devices.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4UL:GR €0.72 EUR -0.026

4UL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Becton Dickinson and Co $151.29 USD +1.17
Insulet Corp $36.58 USD +0.39
West Pharmaceutical Services Inc $64.13 USD +0.51
Ypsomed Holding AG SFr.145.80 CHF +0.20
View Industry Companies

Industry Analysis


Industry Average

Valuation 4UL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 40.4x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.7x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact UNILIFE CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at